Peringatan Keamanan

Side effects include burning sensation, irritation, pruritus, erythema, and skin infections, at the application site.

Pimecrolimus

DB00337

small molecule approved investigational

Deskripsi

Pimecrolimus is an immunomodulating agent that was first marketed by Novartis under the trade name Elidel. It is now promoted in Canada by Galderma since early 2007. It is currently available as a topic cream used in the treatment of atopic dermatitis (eczema).

Struktur Molekul 2D

Berat 810.46
Wujud solid

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) -
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Because of the low systemic absorption of pimecrolimus following topical application the calculation of standard pharmacokinetic measures such as AUC, Cmax, half-life, etc. cannot be reliably done.

Metabolisme

No drug metabolism was observed in human skin in vitro. Oral administration yielded metabolites produced from O-demethylation and oxygenation reactions.

Rute Eliminasi

80% of the drug is excreted in the feces.

Interaksi Obat

309 Data
Etanercept The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Etanercept.
Peginterferon alfa-2a The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Peginterferon alfa-2a.
Interferon alfa-n1 The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Interferon alfa-n1.
Interferon alfa-n3 The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Interferon alfa-n3.
Peginterferon alfa-2b The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Peginterferon alfa-2b.
Anakinra The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Anakinra.
Interferon gamma-1b The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Interferon gamma-1b.
Interferon alfa-2a The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Interferon alfa-2a.
Aldesleukin The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Aldesleukin.
Adalimumab The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Adalimumab.
Gemtuzumab ozogamicin The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Gemtuzumab ozogamicin.
Pegaspargase The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Pegaspargase.
Infliximab The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Infliximab.
Interferon beta-1b The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Interferon beta-1b.
Interferon alfacon-1 The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Interferon alfacon-1.
Trastuzumab The risk or severity of neutropenia can be increased when Trastuzumab is combined with Pimecrolimus.
Rituximab The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Rituximab.
Basiliximab The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Basiliximab.
Muromonab The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Muromonab.
Ibritumomab tiuxetan The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Ibritumomab tiuxetan.
Tositumomab The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Tositumomab.
Alemtuzumab The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Alemtuzumab.
Cyclosporine The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Cyclosporine.
Alefacept The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Alefacept.
Efalizumab The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Efalizumab.
Antithymocyte immunoglobulin (rabbit) The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Antithymocyte immunoglobulin (rabbit).
Interferon alfa-2b The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Interferon alfa-2b.
Natalizumab The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Natalizumab.
Daclizumab The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Daclizumab.
Phenylalanine The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Phenylalanine.
Flunisolide The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Flunisolide.
Bortezomib The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Bortezomib.
Cladribine Pimecrolimus may increase the immunosuppressive activities of Cladribine.
Carmustine The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Carmustine.
Amsacrine The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Amsacrine.
Bleomycin The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Bleomycin.
Chlorambucil The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Chlorambucil.
Raltitrexed The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Raltitrexed.
Mitomycin The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Mitomycin.
Bexarotene The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Bexarotene.
Vindesine The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Vindesine.
Floxuridine The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Floxuridine.
Indomethacin The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Indomethacin.
Tioguanine The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Tioguanine.
Vinorelbine The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Vinorelbine.
Dexrazoxane The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Dexrazoxane.
Beclomethasone dipropionate The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Beclomethasone dipropionate.
Sorafenib The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Sorafenib.
Streptozocin The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Streptozocin.
Trifluridine The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Trifluridine.
Gemcitabine The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Gemcitabine.
Betamethasone The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Betamethasone.
Teniposide The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Teniposide.
Epirubicin The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Epirubicin.
Chloramphenicol The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Chloramphenicol.
Lenalidomide The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Lenalidomide.
Altretamine The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Altretamine.
Zidovudine The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Zidovudine.
Cisplatin The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Cisplatin.
Oxaliplatin The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Oxaliplatin.
Cyclophosphamide The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Cyclophosphamide.
Vincristine The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Vincristine.
Fluorouracil The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Fluorouracil.
Propylthiouracil The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Propylthiouracil.
Pentostatin The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Pentostatin.
Methotrexate The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Methotrexate.
Carbamazepine The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Carbamazepine.
Vinblastine The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Vinblastine.
Fluticasone propionate The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Fluticasone propionate.
Fluocinolone acetonide The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Fluocinolone acetonide.
Linezolid The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Linezolid.
Imatinib The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Imatinib.
Triamcinolone The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Triamcinolone.
Clofarabine The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Clofarabine.
Prednisone The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Prednisone.
Pemetrexed The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Pemetrexed.
Fludrocortisone The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Fludrocortisone.
Mycophenolate mofetil The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Mycophenolate mofetil.
Daunorubicin The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Daunorubicin.
Hydrocortisone The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Hydrocortisone.
Irinotecan The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Irinotecan.
Methimazole The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Methimazole.
Etoposide The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Etoposide.
Sulfasalazine The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Sulfasalazine.
Dacarbazine The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Dacarbazine.
Temozolomide The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Temozolomide.
Penicillamine The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Penicillamine.
Prednisolone The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Prednisolone.
Sirolimus The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Sirolimus.
Mechlorethamine The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Mechlorethamine.
Azacitidine The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Azacitidine.
Carboplatin The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Carboplatin.
Methylprednisolone The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Methylprednisolone.
Dactinomycin The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Dactinomycin.
Cytarabine The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Cytarabine.
Azathioprine The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Azathioprine.
Doxorubicin The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Doxorubicin.
Hydroxyurea The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Hydroxyurea.
Busulfan The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Busulfan.
Mycophenolic acid The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Mycophenolic acid.

Target Protein

Protein phosphatase 3 catalytic subunit alpha PPP3CA
Serine/threonine-protein kinase mTOR MTOR
Peptidyl-prolyl cis-trans isomerase FKBP1A FKBP1A

Referensi & Sumber

Synthesis reference: Viktor Gyollai, Csaba Szabo, "Methods of preparing pimecrolimus." U.S. Patent US20060142564, issued June 29, 2006.
Artikel (PubMed)
  • PMID: 10468798
    Grassberger M, Baumruker T, Enz A, Hiestand P, Hultsch T, Kalthoff F, Schuler W, Schulz M, Werner FJ, Winiski A, Wolff B, Zenke G: A novel anti-inflammatory drug, SDZ ASM 981, for the treatment of skin diseases: in vitro pharmacology. Br J Dermatol. 1999 Aug;141(2):264-73.

Contoh Produk & Brand

Produk: 16 • International brands: 2
Produk
  • Elidel
    Cream • 10 mg/1g • Topical • US • Approved
  • Elidel
    Cream • 10 mg/1g • Topical • US • Approved
  • Elidel
    Cream • 10 mg/1g • Topical • US • Approved
  • Elidel
    Cream • 10 mg/1g • Topical • US • Approved
  • Elidel
    Cream • 10 mg/1g • Topical • US • Approved
  • Elidel
    Cream • 10 mg/1g • Topical • US • Approved
  • Elidel
    Cream • 1 % w/w • Topical • Canada • Approved
  • Pimecrolimus
    Cream • 10 mg/1g • Topical • US • Generic • Approved
Menampilkan 8 dari 16 produk.
International Brands
  • Aregen — Meda Pharm
  • Rizan — Esteve

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul